NewswireToday - /newswire/ -
Fremont, CA, United States, 2012/07/30 - ß-Amyloid (1-40) together with ß-Amyloid (1-42) are two major C-terminal variants of the Aß protein constituting the majority of Aßs, with Ab (1-42) being more neurotoxic.
These undergo post-secretory aggregation and deposition in the Alzheimer’s diseased brain.1-5
AnaSpec, EGT Group is pleased to be a provider of a large collection of ß-Amyloid (1-40) peptides with Native sequences, human and mouse/rat sequences (unless otherwise specified, sequences are human in origin), Single or multiple amino acid substitution sequences, e.g. S26C, Biotin labeled sequences – N or C terminally labeled, with or without linker, Dye labeled sequences (HiLyte Fluor™ or classic dye labeled), ClearPoint™ heavy-isotope labeled sequences, Shorter sequences that end on the 40th amino acid and analog and HFIP treated ß-Amyloid (1-40)
1. Masters, CL. et al. Proc Natl Acad Sci USA 82, 4245 (1985).
2. Yankner, BA. Neuron 16, 921 (1996).
3. Geula, C. et al. Nat Med 4, 827 (1998).
4. Shin, R. et al. J Neurosci 17, 8187 (1997).
5. Suzuki, N. et.al. Science 264, 1336 (1994).
AnaSpec, EGT Group
AnaSpec, Eurogentec Group is a leading provider of integrated proteomics and genomics solutionsTM for worldwide life science research. AnaSpec offers expertise in peptides, detection reagents, antibodies, assay kits, amino acids, oligonucleotides, and qPCRs. AnaSpec carries a broad product line of biochemicals and reagents for basic research, high-throughput screening and drug discovery. AnaSpec also provides premier custom services including peptide synthesis, antibody production, assay development, fluorescent dyes, and oligonucleotide synthesis. AnaSpec is certified to ISO 9001:2008.